CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 40 enrolled
Drug / intervention
Sham light +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00818246
NCT00818246Phase 3Completed

Non-ablative Light Source for the Treatment of Rhytides (Wrinkles)

RoseLab Skin Optics Laboratory·interventional·Posted Jan 7, 2009·Updated Nov 16, 2009

In Brief

A Phase 3 clinical trial evaluating Sham light and LumiPhase-R™, OPUSMED Inc. Montreal, Canada for Skin Aging and Photoaging of Skin. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study was to determine whether light emitting diode (LED) therapy can improve skin appearance of human subjects with aged/photoaged skin. A reduction in rhytid depth as well as in skin surface roughness and in the degree of elastosis after LED treatments was expected.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 7, 2009
TodayJul 2, 2026
Posted 17.5 years ago

Interventions

Sham lightdevice

LumiPhase-R™, OPUSMED Inc. Montreal, Canadadevice

660 nm wavelength delivered in a sequential pulsing mode